SEC Filing Update: #IKT Inhibikase Therapeutics, Inc. : $2.41

Sector: Healthcare | YTD: 🔼+ 23.59% The SEC disclosed Today (14-AUG-2026) that NANTAHALA CAPITAL MANAGEMENT, L has INCREASED #IKT Shares by 115.05% 🟢 * Previous Holdings: 2.70M Shares * Current Holdings: 5.81M Shares * Increase+3.11M * Increased(%)+115.05% * Ownership: 4.3% * Estimated Investment Value: $7.46M https://www.thinksabio.com/reports/isr/IKT Institutional ownership in #IKT has been steadily rising over the past 9 quarters in Shares: Q1 2024: 205.56K Q2 2024: 836.50K Q3 2024: 860.23K Q4 2024: 50.06M Q1 2025: 51.46M Q2 2025: 54.51M Q3 2025: 54.96M Q4 2025: 106.42M Q1 2026: 115.14M The quarterly average prices of #IKT: Q1 2026: $1.78 📌 Institutional activity in the last 30 days for #IKT: • RA CAPITAL MANAGEMENT – Newly bought 25,000,000 shares (17-JUL-2026) • BLACKROCK INC – Increased holdings by 1,464,571 shares (28-JUL-2026)